Oct. 22, 2025 — Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS), recently announced the first patients dosed in Part B of its Phase 2 RAISE trial of BB-031. BB-031 is an investigational RNA aptamer targeting von Willebrand Factor (vWF), a key mediator of clot formation and stabilization.

Oct. 21, 2025 — Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam has reported promising results from its pivotal VALID-ECG study (https://ibn.fm/BDiIa), demonstrating that its synthesized 12-lead ECG technology delivers a strong correlation with the clinical gold standard of traditional 12-lead ECGs for non-life-threatening arrhythmias. 

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, has announced the publication in peer-reviewed journal Nature Medicine of 12-month data from its Phase 1 trial of AB-1002 investigational gene therapy in participants with congestive heart failure (CHF).1

Oct. 21, 2025 — GE HealthCare has received CE mark for its Carevance patient monitor, advancing accessible and reliable care for more customers starting in Europe. Carevance offers a clinically reliable and cost-effective solution with validated parameters and an intuitive, efficient workflow that can help empower care teams to stay focused on their patients.

Oct. 21, 2025 — At the seventeenth edition of the World Stroke Congress in Barcelona, Siemens Healthineers will present the Mobile Stroke Unit (MSU). This is the first mobile unit capable of diagnosing and treating stroke at the location where it occurs.

Oct. 20, 2025 – Brainomix, a provider of AI-powered imaging tools in lung fibrosis and stroke, will present new evidence at the CHEST Annual Meeting in Chicago showing its Brainomix 360 e-Lung technology could have significantly accelerated the diagnosis of Progressive Pulmonary Fibrosis (PPF) in over half of patients by up to almost two years.

Oct. 16, 2025 — Thirona recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for LungQ 4, the latest version of its AI-powered CT analysis software.

This new clearance builds on version 3 of LungQ, cleared by the FDA last year, which introduced advanced lung segmentation capabilities — a critical foundation for accurate analysis on a regional level. 

LungQ 4 extends these capabilities into:

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association (HCMA), the leading advocacy group representing patients and families affected by hypertrophic cardiomyopathy. The partnership will accelerate patient recruitment and engagement in the ongoing Fortitude-HCM study, a Phase 2b clinical trial evaluating ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a debilitating disease with no currently approved treatments.

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the United States for the Synchrony system.

Oct. 15, 2025 — MedAxiom has released its 2025 Cardiovascular Provider Compensation and Production Survey report that includes data from the largest number of programs since its debut.

2025 MedAxiom Cardiovascular Provider Compensation and Production Survey report aggregates data on private vs. integrated practice, APP to physician ratios, patient volumes and subspeciality considerations.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now